Key facts

Active substance
Nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171)
Therapeutic area
Neonatology-Paediatric Intensive Care
Decision number
PIP number
Pharmaceutical form(s)
Nebuliser solution
Condition(s) / indication(s)
Treatment of lower respiratory tract disease caused by human respiratory syncytial virus (RSV)
Route(s) of administration
Inhalation use
Contact for public enquiries
Ablynx NV 

Tel. +32 92620000 
E-mail: regulatory@ablynx.com

Decision type
PM: decision on the application for modification of an agreed PIP


How useful was this page?

Add your rating